Vol 11, No 3 (2010): Practical Diabetology
Research paper
Published online: 2010-11-05

open access

Page views 584
Article views/downloads 3914
Get Citation

Connect on Social Media

Connect on Social Media

Influence of selected inflammatory markers on occurrence and duration of partial remission in patients with type 1 diabetes

Paweł Niedźwiecki, Stanisław Piłaciński, Aleksandra Uruska, Paweł Uruski, Dorota Zozulińska-Ziółkiewicz, Bogna Wierusz-Wysocka
Diabetologia Praktyczna 2010;11(3):94-100.

Abstract


INTRODUCTION. Aim of the study was to asses the influence of selected inflammatory markers on occurrence and duration of remission in type 1 diabetes.
MATERIAL AND METHODS. 224 patients with newly diagnosed type 1 diabetes were qualified to the study. Partial remission was defined as HbA1c below 7% and daily exogenous insulin requirement below 0.5 U/kg and positive C-peptide level. The occurrence and duration of remission was assessed during regular visits in out-patient clinic. We divided patients according to occurrence of remission and its duration (above and below 1 year). The following inflammatory markers were taken into account: white blood cell count (WBC), serum C-reactive protein concentration (CRP), erythrocyte sedimentation rate (ESR), and concentration of serum myeloperoxidase (MPO).
RESULTS. 175 patients achieved partial remission. When compared with patients who did not experience remission remittents showed lower WBC (6.2 ± ± 1.4 v. 7.1 ± 2.7 103/ul; p < 0.03) and ESR (5.1 ± ± 3.3 v. 8.3 ± 12.2 mm/h; p < 0.02). Patients with shorter duration of remission had higher serum MPO level (250.6 ± 139.5 v. 163.9 ± 82.7 ng/ml; p = 0.008). Using logistic regression, significant association between serum MPO level (OR = 0.34, 95% CI: 0.12– –0.94; p < 0.03) and duration of remission was found.
CONCLUSIONS. The results of this study show that inflammatory process influences occurrence and duration of remission in patients with type 1 diabetes. MPO seems to be a prognostic marker of duration of remission. The higher serum concentration of the MPO, the shorter duration of remission in patients with type 1 diabetes. (Diabet. Prakt. 2010; 11, 3: 94–100)

Article available in PDF format

View PDF Download PDF file